Vafidemstat-ORY-2001-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEVafidemstatCat.No.:HY-112623CASNo.:1357362-02-7Synonyms:ORY-2001分?式:C??H??N?O?分?量:336.39作?靶點(diǎn):HistoneDemethylase;MonoamineOxidase作?通路:Epigenetics;NeuronalSignaling儲(chǔ)存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(148.64mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.9727mL14.8637mL29.7274mL5mM0.5945mL2.9727mL5.9455mL10mM0.2973mL1.4864mL2.9727mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:5mg/mL(14.86mM);Suspendedsolution;Needultrasonic1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:5mg/mL(14.86mM);Suspendedsolution;Needultrasonic3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥5mg/mL(14.86mM);ClearsolutionBIOLOGICALACTIVITY?物活性Vafidemstat(ORY-2001)?種有效的，具有?服活性的，可透過?腦屏障的，雙重的賴氨酸特異性組蛋?去甲化酶(LSD1)/MAO-B抑制劑[1]。IC50&TargetLSD1/MAO-B[1]體外研究Vafidemstat(ORY-2001),adualLSD1/MAO-Binhibitor,isanovelepigeneticagentforthetreatmentofneurodegenerativediseases.LSD1isaproteinthatparticipatesintranscriptionregulationcomplexes;itsmodulationcanbeusedtotweaktranscriptionalimbalancesinneurodegenerativediseaseandredressneuroinflammationandcognitivedeficit[1].Vafidemstat(ORY-2001)canbeusedinthetreatmentofAlzheimer'sdisease[2].REFERENCES[1].ORYZONpresentsdataonthePhaseItrialwithORY-2001atthe13thInternationalConferenceonAlzheimer’sandParkinson’sdiseases[2].ORYZONReportsFinancialResultsandCorporateUpdateforthe1stHalfEndedJune30,2018.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel